Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Meeting in London news should come later this morning. Looking for $2.25-$2.60 EOD IMO.
press release
Nov. 20, 2013, 8:00 a.m. EST
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
NEW YORK, November 20, 2013 /PRNewswire via COMTEX/ -- Editor Note: For more information about this release, please scroll to bottom
Today, Analysts' Corner announced new research reports highlighting Cell Therapeutics, Inc. /quotes/zigman/11692802/delayed/quotes/nls/ctic CTIC +2.12% , Akorn, Inc. /quotes/zigman/67758/delayed/quotes/nls/akrx AKRX +2.53% , Ligand Pharmaceuticals Incorporated /quotes/zigman/1626750/delayed/quotes/nls/lgnd LGND +1.91% , Intercept Pharmaceuticals, Inc. /quotes/zigman/12230574/delayed/quotes/nls/icpt ICPT +3.12% , and Ariad Pharmaceuticals Inc. /quotes/zigman/57221/delayed/quotes/nls/aria ARIA +1.53% . Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Research Report Cell Therapeutics, Inc. (Cell Therapeutics) along with Baxter International Inc. (Baxter) announced that the two have entered into an exclusive worldwide licensing agreement to develop and commercialize pacritinib - a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia, and certain solid tumors. Cell Therapeutics stated that under the terms of the agreement, Baxter gains exclusive commercialization rights for all indications for pacritinib outside the U.S., and the Company will commercialize pacritinib in the U.S. together with Baxter. Commenting on the agreement, James A. Bianco, M.D. President and CEO of Cell Therapeutics stated, "We believe Baxter represents the ideal strategic partner to achieve the full potential of pacritinib. Our two companies share a dedication to oncology and a vision for bringing this unique oral JAK2/FLT3 inhibitor to patients with certain blood cancers and solid tumors. This collaboration will provide additional financial resources and commercial expertise to position us to pursue the development, commercialization and market potential of pacritinib."
$2.25-$2.30 with good news tomorrow IMO.
Look for a strong close EOD with anticipation of good news tomorrow!
I'm predicting good news out of London on wednesday will push PPS to $2.50-$3.00 this week.
Good news at Jefferies Conference in London on wednesday should drive stock price in strong positive direction.
BEHOLD THE POWER HOUR IS UPON US! FAST & FURIOUS CLOSE IS EXPECTED HERE!
What's good is EOD run to $3.50-$3.60!!!!
What's good is EOD run to $3.50-$3.60!!!!
Anyone care to speculate on PPS at EOD? $3.50??
I Look for $3.50-$3.60 Close Today.
SHAKE OFF AND ROCKET BACK BABY!!!!
Only minor dips from here. I predict $5 by Thanksgiving!
PERSING SQUARE INVESTMENT
By Silvia Ascarelli FNMA NEW YORK (MarketWatch) - Pershing Square Capital Management LP and its chief executive, Bill Ackman, disclosed a 9.77% stake in the Federal Home Loan Mortgage Corp. /quotes/zigman/226335/delayed/quotes/nls/fmcc FMCC +11.03% , more commonly known as Freddie Mac, and a 9.98% stake in the Federal National Mortgage Association /quotes/zigman/226360/delayed/quotes/nls/fnma FNMA +11.76% , commonly known as Fannie Mae, according to filings Friday with the Securities and Exchange Commission. Pershing said it has acquired 63.5 million common shares in Freddie Mac and 115.6 million common shares in Fannie Mae and described both as undervalued. The moves come two day after Fairholme Capital Management, a Miami-based mutual-fund company, offered to buy parts of Freddie Mac and Fannie Mae and recapitalize them.
Next run will blow past $3.50!!
This SOB may go to $4 TODAY!
Outstanding! Should be a profitable day! : )
Agreed, we should see $3.50-$4 before close tomorrow.
$5 BY THANKSGIVING PEOPLE!
OH MY! TALK ABOUT SWEEET!!!
I expect we will see $3.50 before close tomorrow. what do you think?
$3 $3 $3 $3!
Fall back and bounce hard baby! There's too much momentum and good news for this stock to stay at this low price!
Looks like $3 today!
Sure glad I did'nt sell yesterday! It's looking like we may recover STRONG!